The Rationale for “Use the Best First”: Introduction to the Proceedings

References

• Ehrlich P. Chemotherapeutics: Scientific principles, methods and results. Lancet. 1913; II: 445-451.
   Google Scholar
• Spellberg B, Powers JH, Brass EP et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38(9):1279-86.
   Google Scholar
• Shlaes DM, Projan SJ, Edwards JE. Antibiotic Discovery: State of the State. ASM News 70:275-281, 2004.
   Google Scholar
• Blondeau JM, Hansen G, Metzler K et al. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004; 16 Suppl 3: 1-19
   Google Scholar
• Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003, 9, 1: 1-9
   Google Scholar
• Tillotson G. Deja-vu: A ‘New’ Approach To Managing Bacterial Infections. Pulmonary Perspectives December 2003: 7-9.
   Google Scholar
• Levy SB & Marshall B. Antibacterial resistance word-wide: causes, challenges and responses Nature Med. 2004; 10:S122-S129
   Google Scholar
• Cockerill FR 3rd, Smith TF. Response of the clinical microbiology laboratory to emerging (new) and reemerging infectious diseases. J Clin Microbiol. 2004;42(6):2359-65.
   Google Scholar
• McDonald PJ, Pruul H. Tailoring Antibiotic Treatment to Host Immune Status: The Host, Not the Drug, Determines Outcome. Curr Infect Dis Rep. 2001;3(4):309-311.
   Google Scholar
• Eandi M. Unità di consumo dei farmaci e valutazioni farmacoeconomiche: uso e misuso di DDD e PDD. Farmacoeconomia e percorsi terapeutici. 2002; 3(4): 209-222.
   Google Scholar
• Grassi C, Casali L, Curti E et al. SMART Study Group. Studio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni de Bronchite Cronica. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother. 2002;14(6):597-608.
   Google Scholar
• Talan DA. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001;32 Suppl 1:S64-71.
   Google Scholar
• Grasela TH Jr, Paladino JA, Schentag JJ et al. Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics. DICP. 1991;25(7-8):857-62.
   Google Scholar
• Klugman KP, Capper T. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin. J Antimicrob Chemother. 1997;40(6):797-802.
   Google Scholar
• Jones ME, Blosser-Middleton RS, Critchley IA et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin Microbiol Infect. 2003;9(7):590-9.
   Google Scholar
• Schito AM, Schito GC, Debbia E et al. Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999-2000. J Chemother. 2003; 15 (3): 226-34.
   Google Scholar
• Felmingham D, Reinert RR, Hirakata Y et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002;50 Suppl S1:25-37.
   Google Scholar
• Hoban DJ, Doern GV, Fluit AC et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32 Suppl 2:S81-93.
   Google Scholar
• Fadda G, Nicoletti G, Schito GC. Progetto Nazionale per la sorveglianza delle infezioni batteriche gravi in ambito comunitario e ospedaliero. Istituto Superiore della Sanità 2004.
   Google Scholar
• Polk RE, Johnson CK, McClish D et al. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis. 2004;39(4):497-503.
   Google Scholar
• Bhavnani SM, Hammel JP, Jones RN et al. Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diagn Microbiol Infect Dis. 2005;51(1):31-7.
   Google Scholar
• Niederman MS. Reexamining quinolone use in the intensive care unit: use them right or lose the fight against resistant bacteria. Crit Care Med. 2005;33(2):443-4.
   Google Scholar
• Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent Infections. Science 1999; 248, 5418: 1318-1322.
   Google Scholar
• Donland RM, Costerton JW. Biofilms: survival mechanism of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15, 2: 167-193.
   Google Scholar
• Hansen G, Ekert L, Mezler K et al. Comparison of the Minimun Inhibitory Concentration, Mutant Prevention Concentration and Bactericidal Concentration of Ciprofloxacin and Levofloxacin against enteric Gram-negative bacilli. Poster presentato all’ICAAC 2002; N. E-70.
   Google Scholar
• Hyatt JM, McKinnon PS, Zimmer GS et al. The importance of pharmacokinetic/ pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet. 1995;28(2):143-60.
   Google Scholar
• Metzler K, Hansen GM, Hedlin P et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int J Antimicrob Agents. 2004;24(2):161-7.
   Google Scholar
• Drlica K, Schmitz FJ. Therapeutic options in an era of decreasing antimicrobial susceptibility. J Chemother. 2002;14 Suppl 2:5-12.
   Google Scholar
• Allen GP, Kaatz GW, Rybak MJ. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int J Antimicrob Agents. 2004;24(2):150-60.
   Google Scholar
• Blondeau JM, Hansen GT. Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. Expert Opin Pharmacother. 2001;2(2):317-35.
   Google Scholar
• Andes D & Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19:261-268.
   Google Scholar
• Fantin B, Legget J, Ebert S, Craig WA. Correlation between in vitro and in vivo activity of antimicrobial agents against Gram-negative bacilli in a murine infection model. Antimicrob agents chemother 1991; 35 (7): 1413-1422.
   Google Scholar